Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights
November 12, 2024 07:00 ET
|
Optinose, Inc.
Company reports Q3 2024 XHANCE net revenue of $20.4 million, an increase of 3% compared to Q3 2023 Company reports positive inflection in new prescriptions of XHANCE starting in September Company...
Optinose Announces Reporting Date for Third Quarter 2024 Financial Results
November 05, 2024 16:30 ET
|
Optinose, Inc.
YARDLEY, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Appoints Terry Kohler as Chief Financial Officer
October 07, 2024 16:59 ET
|
Optinose, Inc.
YARDLEY, Pa., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery
September 05, 2024 09:00 ET
|
Optinose, Inc.
YARDLEY, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference
August 26, 2024 09:00 ET
|
Optinose, Inc.
YARDLEY, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports Second Quarter 2024 Financial Results and Recent Operational Highlights
August 08, 2024 07:00 ET
|
Optinose, Inc.
Company reports Q2 2024 XHANCE net revenue of $20.5 million, an increase of 5% compared to Q2 2023 XHANCE has been added to Express Scripts’ national formularies, among the largest commercial...
Optinose Announces Reporting Date for Second Quarter 2024 Financial Results
August 02, 2024 08:30 ET
|
Optinose, Inc.
YARDLEY, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Expanded Access to XHANCE with Addition to National Commercial Formularies
June 27, 2024 07:00 ET
|
Optinose, Inc.
YARDLEY, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
May 17, 2024 12:00 ET
|
Optinose, Inc.
YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights
May 14, 2024 07:00 ET
|
Optinose, Inc.
Company reports Q1 2024 XHANCE net revenue of $14.9 million, an increase of 26% compared to Q1 2023 Company expects full year 2024 XHANCE net revenues to be between $85.0 to $95.0 million ...